Contrast-induced nephropathy

Journal of Interventional Cardiology

Volumn 21, Issue 1, 2008, Pages 74-85

  Bartorelli, Antonio L ^a,b   Marenzi, Giancarlo ^a  

^a UNIVERSITY OF MILAN   (Italy)

^b CENTRO CARDIOLOGICO MONZINO   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLCYSTEINE; AMLODIPINE; ARGININE; ASCORBIC ACID; ATRIAL NATRIURETIC FACTOR; BICARBONATE; CAPTOPRIL; CONTRAST MEDIUM; DIATRIZOATE; DILTIAZEM; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; FELODIPINE; FENOLDOPAM; GLUCOSE; ILOPROST; IODIXANOL; IOHEXOL; IOPAMIDOL; IOPROMIDE; IOXAGLIC ACID; NIFEDIPINE; NITRENDIPINE; OXYGEN; SODIUM CHLORIDE; THEOPHYLLINE; TRIMETAZIDINE; VERAPAMIL;

ANEMIA; AORTA BALLOON; ARTICLE; CHRONIC KIDNEY DISEASE; CLINICAL FEATURE; COMBINATION CHEMOTHERAPY; COMORBIDITY; CONTRAST INDUCED NEPHROPATHY; CREATININE BLOOD LEVEL; DIABETES MELLITUS; DISEASE COURSE; EVENING DOSAGE; HEART FAILURE; HEMOFILTRATION; HUMAN; HYDRATION; KIDNEY DISEASE; KIDNEY TRANSPLANTATION; MONOTHERAPY; MORNING DOSAGE; PATHOPHYSIOLOGY; PERCUTANEOUS CORONARY INTERVENTION; PRIORITY JOURNAL; PROGNOSIS; RENAL REPLACEMENT THERAPY; RISK FACTOR; SINGLE DRUG DOSE;

ANTIOXIDANTS; CONTRAST MEDIA; HUMANS; PROGNOSIS; RENAL REPLACEMENT THERAPY; RISK FACTORS; VASODILATOR AGENTS;

EID: 38749114693     PISSN: 08964327     EISSN: 15408183     Source Type: Journal    
DOI: 10.1111/j.1540-8183.2007.00318.x     Document Type: Article

References (83)

1. Gupta R, Binbaum Y, Uretsky BF. The renal patient with coronary artery disease. Current concepts and dilemmas. J Am Coll Cardiol 2004 44 : 1343 1353.
2. Nash K, Hafeez A, Hou S. Hospital-acquired renal insufficiency. Am J Kidney Dis 2002 39 : 930 936.
3. Gruber L. Clinical features and prognostic implications of contrast-induced nephropathy. In Bartorelli AL, Marenzi G, eds. Contrast-Induced Nephropathy. London : Taylor & Francis, 2006, pp. 35 45.
4. US Renal Data System/National Institutes of Health. Annual data report: Atlas of end-stage renal disease in the United States. 2006. http://wwwusrds.org/adr.htm.
5. Barrett BJ, Parfrey PS. Preventing nephropathy induced by contrast medium. N Engl J Med 2006 354 : 379 386.
6. Persson PB, Tepel M. Contrast medium-induced nephropathy: The pathophysiology. Kidney Int 2006 69 (Suppl. 100 S8 S10.
7. McCullough PA, Dandberg KR. Epidemiology of contrast-induced nephropathy. Rev Cardiovasc Med 2003 4 (Suppl. 5 1172 1181.
8. McCullough PA, Wolyn R, Rocher LL, et al. Acute renal failure after coronary intervention: Incidence, risk factors and relationship to mortality. Am J Med 1997 103 : 368 375.
9. Mehran R, Aymong ED, Nikolsky E, et al. A simple risk score for prediction of contrast-induced nephropathy after percutaneous coronary intervention. J Am Coll Cardiol 2004 44 : 1393 1399.
10. Cochran ST, Wong WS, Roe DJ. Predicting angiography-induced acute renal function impairment: Clinical risk model. Am J Roentgenol 1983 141 : 1027 1033.
11. Rich MW, Crecelius CA. Incidence, risk factors and clinical course of acute renal insufficiency after cardiac catheterization in patients 70 years of age or older. A prospective study. Arch Intern Med 1990 150 : 1237 1242.
12. Bartholomew BA, Harjai KJ, Dukkipati S, et al. Impact of nephropathy after percutaneous coronary intervention and a method for risk stratification. Am J Cardiol 2004 93 : 1515 1519.
13. Rihal CS, Textor SC, Grill DE, et al. Incidence and prognostic importance of acute renal failure after percutaneous coronary intervention. Circulation 2002 105 : 2259 2264.
14. Gruber L, Mehran R, Dangas G, et al. Acute renal failure requiring dialysis after percutaneous coronary interventions. Catheter Cardiovasc Interv 2001 52 : 409 416.
15. Marenzi G, Lauri G, Assanelli E, et al. Contrast-induced nephropathy in patients undergoing primary angioplasty for acute myocardial infarction. J Am Coll Cardiol 2004 44 : 1780 1785.
16. Erley CM. Does hydration prevent radiocontrast-induced acute renal failure? Nephrol Dial Transplant 1999 14 : 1064 1066.
17. Solomon R, Werner C, Mann D, et al. Effects of saline, mannitol, and furosemide on acute decreases in renal function induced by radiocontrast agents. N Engl J Med 1994 331 : 1416 1420.
18. Taylor AJ, Hotchkis D, Morse RW, et al. PREPARED: Preparation for angiography in renal dysfunction. A randomized trial of inpatient vs outpatient hydration protocols for cardiac catheterization in mild to moderate renal dysfunction. Chest 1998 114 : 1570 1574.
19. Trivedi HS, Moore H, Nasr S, et al. A randomized prospective trial to assess the role of saline hydration on the development of contrast nephropathy. Nephron Clin Pract 2003 93 : C29 C34.
20. Stevens MA, McCullough PA, Tobin KJ, et al. A prospective randomized trial of prevention measures in patients at high risk for contrast nephropathy: Results of the PRINCE study. J Am Coll Cardiol 1999 33 : 403 411.
21. Mueller C, Buerkle G, Buettner HJ, et al. Prevention of contrast media-associated nephropathy: Randomized comparison of 2 hydration regimens in 1620 patients undergoing coronary angioplasty. Arch Intern Med 2002 162 : 329 336.
22. Merten GJ, Burgess WP, Gray LV, et al. Prevention of contrast-induced nephropathy with sodium bicarbonate. A randomized controlled trial. JAMA 2004 291 : 2328 2334.
23. Briguori C, Airoldi F, D'Andrea D, et al. Renal insufficiency following contrast adminstration trial (REMEDIAL). A randomized comparison of 3 preventive strategies. Circulation 2007 115 : 1211 1217.
24. Recio-Majoral A, Chaparro M, Prado B, et al. The reno-protective effect of hydration with sodium bicarbonate plus N-acetylcysteine in patients undergoing emergency percutaneous coronary intervention. The RENO study. J Am Coll Cardiol 2007 49 : 1283 1288.
25. Clavijo LC, Pinto TL, Kuchulakanti PK, et al. Effect of a rapid intra-arterial infusion of dextrose 5% prior to coronary angiography on frequency of contrast-induced nephropathy in high-risk patients. Am J Cardiol 2006 97 : 981 983.
26. Briguori C, Marenzi G. Pharmacologic prophylaxis. Kidney Intern 2006 69 : S30 S38.
27. Wang A, Holcslaw T, Bashore TM, et al. Exacerbation of radiocontrast nephrotoxicity by endothelin receptor antagonism. Kidney Int 2000 57 : 1675 1680.
28. Kurnik BR, Allgren RL, Genter FC, et al. Prospective study of atrial natriuretic peptide for the prevention of radiocontrast-induced nephropathy. Am J Kidney Dis 1998 31 : 674 680.
29. Neumayer HH, Junge W, Kufner A, et al. Prevention of radiocontrast-media- induced nephrotoxicity by the calcium channel blocker nitrendipine: A prospective randomized clinical trial. Nephrol Dial Transplant 1989 4 : 1030 1036.
30. Spargias K, Adreanides E, Giamouzis G, et al. Iloprost for prevention of contrast-mediated nephropathy in high-risk patients undergoing a coronary procedure. Results of a nonrandomized pilot study. Eur J Clin Pharmacol 2006 62 : 589 595.
31. Ix JH, McCulloch CE, Chertow GM. Theophylline for the prevention of radiocontrast nephropathy: A meta-analysis. Nephrol Dial Transplant 2004 19 : 2747 2753.
32. Cooling DS. Theophylline toxicity. J Emerg Med 1993 11 : 415 425.
33. Abizaid A, Clark CE, Mintz GS, et al. Effects of dopamine and aminophylline on contrast-induced acute renal failure after coronary angioplasty in patients with preexisting renal insufficiency. Am J Cardiol 1999 83 : 260 263.
34. Gare M, Haviv YS, Ben-Yehuda A, et al. The renal effect of low-dose dopamine in high-risk patients undergoing coronary angiography. J Am Coll Cardiol 1999 34 : 1682 1688.
35. Mathur V, Swan S, Lambrecht L, et al. The effects of fenoldopam, a selective dopamine receptor agonist, on systemic and renal hemodynamics in normotensive subjects. Crit Care Med 1999 27 : 1832 1837.
36. Stone GW, McCullough PA, Tumlin JA, et al. Fenoldopam mesylate for the prevention of contrast-induced nephrotoxicity. JAMA 2003 290 : 2284 2291.
37. Miller HI, Dascalu A, Rassin TA, et al. Effects of an acute dose of L-arginine during coronary angiography in patients with chronic renal failure: A randomized, parallel, double-blind clinical trial. Am J Nephrol 2003 23 : 91 95.
38. Gupta RK, Kapoor A, Tewari S, et al. Captopril for prevention of contrast-induced nephropathy in diabetic patients: A randomized study. Indian Heart J 1999 51 : 521 526.
39. DiMari J, Megyesi J, Udvarbelyi N, et al. N-acetylcysteine ameliorates ischemic renal failure. Am J Physiol 1997 272 : F292 F298.
40. Tepel M, Van der Giet M, Schwarzfeld C, et al. Prevention of radiographic-contrast-agent-induced reductions in renal function by acetylcysteine. N Engl J Med 2000 343 : 180 184.
41. Diaz-Sandoval LJ, Kosowsky BD, Losordo DW. Acetylcysteine to prevent angiography-related renal tissue injury (the APART trial). Am J Cardiol 2002 89 : 356 358.
42. Shyu KG, Cheng JJ, Kuan P. Acetylcysteine protects against acute renal damage in patients with abnormal renal function undergoing a coronary procedure. J Am Coll Cardiol 2002 40 : 1383 1388.
43. Kay J, Chow WH, Chan TM, et al. Acetylcysteine for prevention of acute deterioration of renal function following elective coronary angiography and intervention: A randomized controlled trial. JAMA 2003 289 : 553 558.
44. Briguori C, Manganelli F, Scarpato P, et al. Acetylcysteine and contrast-agent associated nephrotoxicity. J Am Coll Cardiol 2002 40 : 298 303.
45. Birck R, Krzossok S, Markowetz F, et al. Acetylcysteine for prevention of contrast nephropathy. Lancet 2003 362 : 598 603.
46. Isenbarger D, Kent S, O'Malley P. Meta-analysis of randomized clinical trials on the usefulness of acetylcysteine for prevention of contrast nephropathy. Am J Cardiol 2003 92 : 1454 1458.
47. Alonso A, Lau J, Jaber BL, et al. Prevention of radiocontrast nephropathy with N-acetylcysteine in patients with chronic kidney disease: A meta-analysis of randomized, controlled trials. Am J Kidney Dis 2004 43 : 1 9.
48. Kshirsagar A, Poole C, Mottl A, et al. N-acetylcysteine for the prevention of radiocontrast induced nephropathy: A meta-analysis of prospective controlled trials. J Am Soc Nephrol 2004 15 : 761 769.
49. Pannu N, Manns B, Lee H, et al. Systematic review of the impact of N-acetylcysteine on contrast nephropathy. Kidney Int 2004 65 : 1366 1374.
50. Guru V, Fremes S. The role of N-acetylcysteine in preventing radiographic contrast-induced nephropathy. Clin Nephrol 2004 62 : 77 83.
51. Bagshaw S, Ghali WA. Acetylcysteine for prevention of contrast-induced nephropathy: A systematic review and meta-analysis. BMC Med 2004 2 : 38.
52. Misra D, Leibowitz K, Gowda R, et al. Role of N-acetylcysteine in prevention of contrast-induced nephropathy after cardiovascular procedures: A meta-analysis. Clin Cardiol 2004 27 : 607 610.
53. Nallamothu BK, Shojania KG, Saint S, et al. Is acetylcysteine effective in preventing contrast-related nephropathy? A meta-analysis. Am J Med 2004 117 : 938 947.
54. Liu R, Nair D, Ix J, et al. N-acetylcysteine for prevention of contrast-induced nephropathy: A systematic review and meta-analysis. J Gen Intern Med 2005 20 : 193 200.
55. Duong M, MacKenzie T, Malenka D. N-Acetylcysteine prophylaxis significantly reduces the risk of radiocontrast-induced nephropathy. Catheter Cardiovasc Interv 2005 64 : 471 479.
56. Tepel M, Aspelin P, Lameire N. Contrast-induced nephropathy: A clinical and evidence-based approach. Circulation 2006 113 : 1799 1806.
57. Baker CSR, Wragg A, Kumar S, et al. A rapid protocol for the prevention of contrast-induced renal dysfunction: The RAPPID study. J Am Coll Cardiol 2003 41 : 2114 2118.
58. Briguori C, Colombo A, Violante A, et al. Standard vs double dose of N-acetylcysteine to prevent contrast agent associated nephrotoxicity. Eur Heart J 2004 25 : 206 211.
59. Marenzi G, Assanelli E, Marana I, et al. N-acetylcysteine and contrast-induced nephropathy in primary angioplasty. N Engl J Med 2006 354 : 2773 2782.
60. Hoffman U, Fischereder M, Kruger B, et al. The value of N-acetylcysteine in the prevention of radiocontrast agent-induced nephropathy seems questionable. J Am Soc Nephrol 2004 15 : 407 410.
61. Zhu J, Yin R, Shao H, et al. N-acetylcysteine to ameliorate acute renal injury in a rat cardiopulmonary bypass model. J Thorac Cardiovasc Surg 2007 133 : 696 703.
62. Haase M, Haase-Fielitz A, Bagshaw SM, et al. Phase II, randomized, controlled trial of high-dose N-acetylcysteine in high-risk cardiac surgery patients. Crit Care Med 2007 35 : 1324 1331.
63. Spargias K, Alexopoulos E, Kyrzopoulos S, et al. Ascorbic acid prevents contrast-mediated nephropathy in patients with renal dysfunction undergoing coronary angiography or intervention. Circulation 2004 110 : 2837 2842.
64. Onbasili AO, Yeniceriglu Y, Agaoglu P, et al. Trimetazidine in the prevention of contrast-induced nephropathy after coronary procedures. Heart 2007 93 : 698 702.
65. Attallah N, Yassine L, Musial J, et al. The potential role of statins in contrast nephropathy. Clin Nephrol 2004 62 : 273 278.
66. Khanal S, Attallah N, Smith DE, et al. Statin therapy reduces contrast-induced nephropathy: An analysis of contemporary percutaneous interventions. Am J Med 2005 118 : 843 849.
67. Moon SS, Back SE, Kurkus J, et al. Hemodialysis for elimination of the nonionic contrast medium iohexol after angiography in patients with impaired renal function. Nephrol 1995 70 : 430 437.
68. Lehnert T, Keller E, Gondolf K, et al. Effect of hemodialysis after contrast medium administration in patients with renal insufficiency. Nephrol Dial Transplant 1998 13 : 358 362.
69. Sterner G, Frennby B, Kurkus J, et al. Does post-angiographic hemodialysis reduce the risk of contrast medium nephropathy? Scand J Urol Nephrol 2000 34 : 323 326.
70. Vogt B, Ferrari P, Schonholzer C, et al. Prophylactic hemodialysis after radiocontrast media in patients with renal insufficiency is potentially harmful. Am J Med 2001 111 : 692 698.
71. Marenzi G, Bartorelli A. Recent advances in the prevention of radiocontrast-induced nephropathy. Curr Opinion Crit Care 2004 10 : 205 209.
72. Marenzi G, Marana I, Lauri G, et al. The prevention of radiocontrast-agent-induced nephropathy by hemofiltration. N Engl J Med 2003 349 : 1331 1338.
73. Marenzi G, Lauri G, Campodonico J, et al. Comparison of two hemofiltration protocols for prevention of contrast-induced nephropathy in high-risk patients. Am J Med 2006 119 : 155 162.
74. Barrett BJ, Carlisle EJ. Metaanalysis of the relative nephrotoxicity of high- and low-osmolality iodinated contrast media. Radiology 1993 188 : 171 178.
75. Rudnick MR, Goldfarb S, Wexler L, et al. Nephrotoxicity of ionic and nonionic contrast media in 1196 patients: A randomized trial. Kidney Int 1995 47 : 254 261.
76. Aspelin P, Aubry P, Fransson SG, et al. Nephrotoxic effects in high-risk patients undergoing angiography. N Engl J Med 2003 348 : 491 499.
77. Boccalandro F, Amhad M, Smalling RW, et al. Oral acetylcysteine does not protect renal function from moderate to high doses of intravenous radiographic contrast. Cathet Cardiovasc Interv 2003 336 341.
78. Chalmers N, Jackson RW. Comparison of iodixanol and iohexol in renal impairment. Br J Radiol 1999 72 : 701 703.
79. Solomon RJ, Natarajan MK, Doucet S, et al. Cardiac angiography in renally impaired patients (CARE) study. A randomized double-blind trial of contrast-induced nephropathy in patients with chronic kidney disease. Circulation 2007 115 : 3189 3196.
80. Feldkamp T, Baumgart D, Elsner M, et al. Nephrotoxicity of iso-osmolar versus low-osmolar contrast media is equal in low risk patients. Clin Nephrol 2006 66 : 322 330.
81. Ni J, Zhang R, Zhang J, et al. J Interv Radiol (Chinese) 2006 15 : 327 329.
82. Barrett BJ, Katzberg RW, Thomsen HS et al. Contrast-induced nephropathy in patients with chronic kidney disease undergoing computed tomography: A double-blind comparison of iodixanol and iopamidol. Invest Radiol 2006 41 : 815 821.
83. Jo SH, Youn TJ, Koo BK, et al. Renal toxicity evaluation and comparison between visipaque (iodixanol) and hexabrix (ioxaglate) in patients with renal insufficiency undergoing coronary angiography: The RECOVER study: A randomized controlled trial. J Am Coll Cardiol 2006 48 : 924 930.